Virotherapy Research in Germany: From Engineering to Translation

Abstract

Virotherapy is a unique modality for the treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Various viruses are being developed as OVs preclinically and clinically, several of them engineered to encode therapeutic proteins for tumor-targeted gene therapy. Scientists and clinicians in German academia have made significant contributions to OV research and development, which are highlighted in this review paper. Innovative strategies for "shielding," entry or postentry targeting, and "arming" of OVs have been established, focusing on adenovirus, measles virus, parvovirus, and vaccinia virus platforms. Thereby, new-generation virotherapeutics have been derived. Moreover, immunotherapeutic properties of OVs and combination therapies with pharmacotherapy, radiotherapy, and especially immunotherapy have been investigated and optimized. German investigators are increasingly assessing their OV innovations in investigator-initiated and sponsored clinical trials. As a prototype, parvovirus has been tested as an OV from preclinical proof-of-concept up to first-in-human clinical studies. The approval of the first OV in the Western world, T-VEC (Imlygic), has further spurred the involvement of investigators in Germany in international multicenter studies. With the encouraging developments in funding, commercialization, and regulatory procedures, more German engineering will be translated into OV clinical trials in the near future.

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors

“…DARPins, in contrast, can be used for receptor-targeting of LV, AAV, adenoviral (AdV), and oncolytic MV vectors. 8 , 16 , 17 Notably, this way such different vector types as LV and AAV can be generated in a way to use an identical binding domain for cell entry. 14 , 15 , 18 …”

A good start of immunotherapy in esophageal cancer

“…Many experts believe that oncolytic virus therapy is perhaps another breakthrough in immunotherapy after the success of ICI . Oncolytic viruses selectively replicate in cancer cells and then induce tumor cells lysis.…”

Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies

“…Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success of CI [31,32]. Oncolytic viruses are defined as genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming the normal tissues.…”